NICE Policy Leader Discusses RWE Trends and Global Impact of COVID-19

The UK’s National Institute for Health and Care Excellence (NICE) recently put forth a five-year strategy plan where it includes guidelines for using real world evidence (RWE). In a recent interview with Aetion, Associate Director for Science Policy and Research at NICE Dr. Páll Jónsson spoke about the widespread impact of RWE and how health technology assessments may shift to incorporate RWE. He noted that the COVID-19 pandemic has led to the acceleration of RWE in drug development.

Dr. Jónsson remarked, “The pandemic itself has brought to us valuable experience, albeit through difficult situations. It has enabled us to, for instance, develop a pipeline of living guidance for COVID, which is intended to be a more dynamic, more frequently updated guidance and takes into account the learnings from the evidence generated as we go along. This experience with COVID-19 is also informing our thinking around how we use RWE more broadly.” Read more here.

(Source: Dr. Páll Jónsson, Aetion, 5/25/21)